Kang Ravinder, Goodney Philip P, Wong Sandra L
Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
J Surg Oncol. 2016 Sep;114(3):275-80. doi: 10.1002/jso.24331. Epub 2016 Jun 22.
The cost of cancer care has increased by five fold over the last three decades. As our healthcare system shifts from volume to value, greater scrutiny of interventions with clinical equipoise is required. Traditionally, QALYs and ICER have served as surrogate markers for value. However, this approach fails to incorporate all stakeholders' viewpoints. Prostate cancer, low risk DCIS, and thyroid cancer are used as a framework to discuss value and cost-effectiveness. J. Surg. Oncol. 2016;114:275-280. © 2016 Wiley Periodicals, Inc.
在过去三十年中，癌症治疗费用增长了五倍。随着我们的医疗保健系统从注重治疗量转向注重治疗价值，需要对具有临床 equipoise 的干预措施进行更严格的审查。传统上，质量调整生命年（QALYs）和增量成本效果比（ICER）一直作为价值的替代指标。然而，这种方法未能纳入所有利益相关者的观点。以前列腺癌、低风险导管原位癌和甲状腺癌为框架来讨论价值和成本效益。《外科肿瘤学杂志》2016 年；114:275 - 280。© 2016 威利期刊公司。
